Data Sheet

Product Name:	Bexarotene
Cat. No.:	CS-0626
CAS No.:	153559-49-0
Molecular Formula:	C24H28O2
Molecular Weight:	348.48
Target:	Autophagy; RAR/RXR
Pathway:	Autophagy; Metabolic Enzyme/Protease
Solubility:	DMSO : 60 mg/mL (172.18 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble)



BIOLOGICAL ACTIVITY:

Bexarotene (LGD1069) is a selective **retinoid X receptors (RXR)** agonist for the treatment of cutaneous T-cell lymphoma.

References:

[1]. Vakeva L, Ranki A, Hahtola S. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland. Acta Derm Venereol. 2012 May;92(3):258-63. doi: 10.2340/00015555-1359.

[2]. Zhang X, Schlaak M, Fabri M, Mauch C, Kurschat P. Successful Treatment of a Panniculitis-Like Primary Cutaneous T-Cell Lymphoma of the α/β Type with Bexarotene. Case Rep Dermatol. 2012 Jan;4(1):56-60.

[3]. Orendas P, Kubatka P, Kajo K, Stollarova N, Kassayova M, Bojkova B, Pec M, Nosal V, Kiskova T, Zihlavnikova K, Karsnakova R. Melatonin enhanced bexarotene efficacy in experimental mammary carcinogenesis. Neoplasma. 2012;59(4):469-74.

[4]. Cras A, Politis B, Balitrand N, Darsin-Bettinger D, Boelle PY, Cassinat B, Toubert ME, Chomienne C. Bexarotene via CBP/p300 induces suppression of NF-κB-dependent cell growth and invasion in thyroid cancer. Clin Cancer Res. 2012 Jan 15;18(2):442-53.

[5]. Gui Y, et al. Bexarotent attenuated CCI-induced spinal neuroinflammation and neuropathic pain by targeting MKP-1. J Pain. 2019 Jan 17. pii: S1526-5900(18)30607-2.

CAIndexNames:

Benzoic acid, 4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]-

SMILES:

CC1(C2=C(C(C)(CC1)C)C=C(C(C(C3=CC=C(C=C3)C(O)=O)=C)=C2)C)C

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA